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Abstract Obesity and related metabolic alterations have
been implicated to play a role in colorectal cancer risk.
The metabolic syndrome, as assessed according to current
international definitions by the key components, abdominal
obesity, dyslipidemia, elevated blood pressure, and abnor-
mal glucose metabolism, is associated with colorectal can-
cer. Recent studies suggest that abdominal obesity and
abnormal glucose metabolism may primarily account for
this association. Visceral adipose tissue is physiologically
more active than subcutaneous adipose tissue and generates
hormones and cytokines with inflammatory, metabolic, and
direct carcinogenic potential, which may directly or indi-
rectly increase colorectal cancer risk. Current evidence sug-
gests that obesity acts as a risk factor for colorectal cancer
by several mechanisms, including chronic low-grade in-
flammation, hyperinsulinemia, as well as alterations in
insulin-like growth factor and adipokine concentrations.
Metabolic biomarkers reflecting these processes may not
only provide clues for etiological understanding of colorec-
tal carcinogenesis but also might be an alternative way to
define an “obesity phenotype” that is relevant for colorectal
cancer development.
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Introduction
Colorectal cancer is the third most common type of cancer
in men and the second most common type in women world-
wide, accounting for approximately 10 % of cancer inci-
dence in both men and women [1]. There is a pronounced
gradient in incidence rates between developing and devel-
oped countries, with highest rates in Australia/New Zealand
and Western Europe and lowest rates in Africa and South-
Central Asia [1]. The high prevalence of obesity has been
hypothesized to be among the factors responsible for the
high incidence of colorectal cancer in most developed
countries [2]. Obesity is associated with a number of meta-
bolic abnormalities, such as elevated blood pressure, abnor-
mal glucose metabolism, and dyslipidemia, which tend to
cluster (referred to as metabolic syndrome) and increase the
risk to develop cardiovascular disease and type 2 diabetes
mellitus. Evidence accumulating during the past decade
suggests that metabolic dysfunctions also may play a role
for colorectal cancer risk. Given the high prevalence of
obesity and colorectal cancer, a better understanding of the
pathophysiology might have important preventive implica-
tions, because it may provide a more accurate and precise
characterization of individuals at risk and it may point to
targets for prevention. The current article reviews the influ-
ence of obesity and related metabolic alterations on
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colorectal cancer risk with a particular emphasis on findings
observed during the past year.
General Adiposity and Risk of Colorectal Cancer
According to the World Health Organization, obesity is “a
condition of abnormal or excessive fat accumulation in
adipose tissue, to the extent that health may be impaired”
[3]. The globally accepted criteria for the definition of
overweight and obesity in adults are based on body mass
index (BMI), calculated as weight (in kilograms) divided by
height (in meters) squared [4]. Based on the Expert Panel on
the Identification, Evaluation, and Treatment of Overweight
and Obesity in Adults, general overweight is defined as BMI
between 25 and 29.9 kg/m2, and general obesity is defined
as BMI ≥30 kg/m2 [4]. The association between obesity as
assessed by BMI and risk of colorectal cancer has been
examined in a number of epidemiological studies, and sev-
eral systematic reviews and meta-analyses have summarized
the existing evidence. The most recent systematic review
came from Ning et al., including 7,213,335 individuals from
56 populations with 93,812 colorectal cancer cases [5]. The
authors found predominantly positive associations in the
studies with an average relative risk (RR) for colorectal
cancer of 1.18 (95 % confidence interval (CI), 1.14–1.21)
per 5 unit higher BMI. The association was significantly
(p00.02) stronger for colon cancer (RR, 1.21; 95 % CI,
1.17-1.26) than for rectal cancer (RR, 1.11; 95 % CI, 1.06-
1.16). This association was significantly (p00.001) stronger
in men (RR, 1.25; 95 % CI, 1.2-1.3) than in women (RR,
1.12; 95 % CI, 1.06-1.16).
Abdominal Obesity and Risk of Colorectal Cancer
Although BMI is correlated with fat mass and associated
with morbidity and mortality, there are a number of limita-
tions. An important drawback of BMI is the inability to
distinguish between fat mass and lean body mass [6]. Fur-
thermore, BMI does not take body fat distribution into
account. Although fat distribution is to some extent
gender-specific, with women usually having a greater
amount of peripherally located subcutaneous fat and men
having a greater amount of centrally located visceral fat,
there also is substantial variation in sex-specific fat distri-
bution for any given BMI. Importantly, viscerally deposited
fat is metabolically more active and secretes greater amounts
of cytokines and hormones compared with subcutaneous
adipose tissue [7]. Furthermore, a higher influx of portal
fatty acids, cytokines, and hormones into the liver from
omental adipose tissue may specifically distort hepatic me-
tabolism, including abnormal lipoprotein synthesis, hepatic
insulin resistance, and increased gluconeogenesis [8]. Body
fat distribution most easily can be assessed by measurement
of waist and hip circumferences. Current guidelines suggest
a waist circumference of 102 cm in men and 88 cm in
women, as being the cutoff points for abdominal obesity
that is associated with an increased risk of morbidity [9, 10].
Assuming that it is primarily visceral adipose tissue and
not nonvisceral adipose tissue that is involved in tumorigen-
ic processes, body weight and BMI may not accurately
reflect the colon cancer risk that is associated with abdom-
inal fat accumulation, particularly in women. This hypothe-
sis has been supported by findings from the European
Prospective Investigation into Cancer and Nutrition (EPIC)
that have indicated that abdominal obesity (as defined by
waist circumference or waist-to-hip ratio) is an equally
strong risk factor for colon cancer in men and women,
whereas body weight and BMI are associated with colon
cancer risk in men but not in women [11]. Thus, men and
women in the highest compared with the lowest gender-
specific quintile of waist-to-hip ratio had a 50 % higher risk
of developing colon cancer over a mean follow-up period of
6 years. This finding has largely been confirmed in a meta-
analysis by Dai and colleagues [12], reporting a pooled
estimate of 1.68 (95 % CI, 1.36, 2.08) for the highest vs.
lowest quintile of waist circumference in men and 1.48
(95 % CI, 1.19, 1.84) in women. The respective estimates
for rectal cancer were 1.26 (95 % CI, 0.9, 1.77) for men and
1.23 (95 % CI, 0.81, 1.86) for women. Furthermore, a meta-
analysis of 21 observational studies on the association be-
tween abdominal obesity and the risk of colorectal adenoma
reported summary relative risks (SRRs) of colorectal ade-
noma to be 1.39 (95 % CI, 1.24-1.56) for the highest versus
the lowest level of waist circumference [13]. Summarizing
the existing research findings, in 2011 the World Cancer
Research Fund judged the existing evidence on body
fatness and abdominal fatness as causes of colorectal
cancer as convincing [14].
Metabolic Syndrome and Risk of Colorectal Cancer
Abdominal obesity is a key component of metabolic syn-
drome (MetS), which is characterized by clustering of met-
abolic abnormalities suggested to play a role in the
development of cardiovascular diseases. According to re-
cent international criteria, components include abdominal
obesity (increased waist circumference), dyslipidemia (ele-
vated triglycerides and low high-density lipoproteins
(HDL)), elevated arterial blood pressure and abnormal glu-
cose metabolism (elevated fasting glucose levels) [9, 10,
15]. The 2009 definition harmonizing the criteria proposed
by several expert panels considers the MetS being present
when any three of the following conditions are given: high
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waist circumference (≥94 cm in men, ≥80 cm in women, for
European population), elevated triglycerides (≥150 mg/dl),
reduced HDL cholesterol (<40 mg/dL in men, >50 mg/dL in
women), elevated blood pressure (systolic ≥130 mmHg, dia-
stolic ≥85 mmHg), fasting glucose level ≥100 mg/dL [15].
Recently, other abnormalities, such as chronic proinflamma-
tory and prothrombotic states, nonalcoholic fatty liver disease,
and sleep apnea, have been proposed in addition to the entity
of the syndrome [16], and there are still no universally accept-
ed diagnostic criteria. Individual components of the metabolic
syndrome have been related to colorectal cancer risk. In
EPIC, high HDL concentrations were significantly associat-
ed with reduced risk of colorectal cancer, whereas no signif-
icant association was observed for triglycerides [17].
Furthermore, in EPIC, a high percentage of glycosylated
hemoglobin (HbA1c), a marker for elevated blood glucose
levels, was statistically significantly associated with higher
colorectal cancer risk [18]. Fasting blood glucose has been
found to be associated with higher risk of colorectal cancer
in a study published last year [19], whereas no association
was observed in another recent study [20]. A number of
studies suggested that MetS is associated with risk of colo-
rectal cancer. A recent meta-analysis summarizing the exist-
ing evidence from cohort studies reported that the presence
of metabolic syndrome was associated with higher risk of
colorectal cancer in both men (RR, 1.25; 95 % CI, 1.19-
1.32) and women (RR, 1.34; 95 % CI, 1.09-1.64), despite
the use of different definitions for MetS [21]. Importantly, it
was shown recently in the EPIC study that among the five
components of MetS, the association of MetS with colon
cancer was largely accounted for by abdominal obesity and
abnormal glucose metabolism, thus highlighting the role of
the excess adipose tissue and associated hyperinsulinemia
and hyperglycemia for risk of colon cancer [22•].
Insulin Resistance, Hyperinsulinemia, and Elevated
Insulin-Like Growth Factors
Hyperinsulinemia has been hypothesized as one of the ma-
jor biological pathways to link obesity and colorectal cancer.
Obesity and especially abdominal adiposity is associated
with insulin resistance, a state when insulin is less effective
in lowering blood glucose levels [23], resulting in elevated
glucose levels (hyperglycemia), and subsequently compen-
satory elevated insulin levels (hyperinsulinemia). Insulin
may influence colorectal carcinogenesis either directly or
indirectly through the potent mitogen insulin-like growth
factor 1 (IGF-1). Hyperinsulinemia enhances the bioactivity
of IGF-1 by up-regulating hepatic IGF-1 synthesis, or by
reducing hepatic secretion of two IGF binding proteins
(IGFBP-1 and IGFBP-2), resulting in higher free or bioac-
tive IGF-1 levels [23, 24]. The insulin and IGF responses
are mediated by insulin receptors (IR) and IGF-1 receptors
(IGF1R), both of which are widely expressed in normal
tissues as well as in epithelial colorectal cancer cells [25].
Binding of insulin or IGF-1 to their receptors is followed by
a signal transduction cascade, which may stimulate cell
proliferation and suppress apoptosis. A plausible support
for the hypothesis that hyperinsulinemia may play a role in
colorectal carcinogenesis comes from observational studies
that found a higher risk of colorectal cancer in individuals
with type 2 diabetes mellitus, which is usually associated
with hyperinsulinemia, compared with individuals without
diabetes. In a recent meta-analysis, comparing individuals
with and without diabetes a significantly increased risk of
colorectal cancer was observed (pooled RR, 1.26; 95 % CI,
1.2-1.31), which did not differ by sex or location of colo-
rectal tumors [26]. There also is evidence that insulin ther-
apy among diabetics is associated with higher risk of
colorectal cancer [26]. Further evidence for a role of the
insulin and IGF-axis in the etiology of colorectal cancer
comes from the observation that patients with acromegaly,
a rare disease of somatic growth accompanied by hyper-
insulinemia and extraordinarily high IGF-1 concentrations
are at increased risk of precancerous adenomatous polyps
and colorectal cancer [27–30].
Higher circulating concentrations of insulin [31] or C-
peptide (a marker of insulin secretion with a longer half-life
than insulin) [32–34] were shown to be associated with a
moderately increased risk of colorectal cancer in a number
of epidemiological studies, whereas in two prospective stud-
ies published during the past year [19, 20] no association
was observed.
The majority of prospective studies investigating circu-
lating IGF-1 levels in relation to colorectal cancer risk
showed positive albeit mostly nonsignificant associations
[35•]. For example, in EPIC, which so far has the largest
study investigating IGF-1 levels in relation to colorectal
cancer risk, there was no significant association [35•]. A
meta-analysis of 11 prospective studies, including the null-
finding from EPIC, showed a moderately significantly in-
creased risk of colorectal cancer, with a RR of 1.07 (95 %
CI, 1.01-1.14) associated with one standard deviation higher
IGF-1 levels [35•]. Taken together, serologic evidence from
observational studies supports the hypothesis that the
positive association between obesity and colorectal can-
cer is at least partly explained by hormonal changes
related to hyperinsulinemia.
Chronic Inflammation
There is substantial evidence that inflammatory processes
play an important role in colorectal carcinogenesis [36].
Thus, studies have shown that individuals with chronic
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inflammatory bowel disease have a higher risk of colorectal
cancer compared with individuals without such a condition
[37, 38]. Furthermore, the use of aspirin and other anti-
inflammatory drugs is associated with a lower risk of colo-
rectal neoplasia [39, 40]. Obesity is associated with chronic
low-grade inflammation due to the production of proinflam-
matory cytokines, such as tumor necrosis factor-alpha
(TNF-alpha) and interleukin-6 (IL-6), which induce the
hepatic secretion of acute phase proteins, such as C-
reactive protein (CRP) [41]. It has been shown that weight
loss reduces inflammatory processes not only systematical-
ly, as seen by reduced CRP-levels [42], but also locally in
the colorectal mucosa [43]. Thus, inflammatory processes
may account, in part, for the positive association between
obesity and colorectal cancer risk.
Findings from epidemiological studies have shown pos-
itive associations between biomarkers of chronic inflamma-
tion (particularly CRP) and colorectal cancer risk. A meta-
analysis from 2008 suggested that CRP concentrations are
weakly positively associated with risk of colon cancer (RR,
1.13; 95 % CI, 1–1.27 per one unit increase in log CRP) and
that this relationship is stronger in men than in women,
whereas no association was found for rectal cancer [44].
CRP has been associated with increased colorectal cancer
risk in 6 of 14 prospective studies published between 2003
and 2011 [45]. One of the more recent and so far the largest
study, a prospective nested case–control study in EPIC
showed significant positive associations between CRP and
colon cancer risk in men and this association was indepen-
dent of BMI and waist circumference, as well as of insulin
resistance and dyslipidemia [46]. In the same study, the
association between CRP and colon cancer in women was
nonsignificant, and no association between CRP and rectal
cancer in either men or women was observed. The three
studies that have investigated the association between cir-
culating CRP and risk of colorectal cancer in women only
[47–49] did not observe positive associations, suggesting
that inconsistency in studies published so far may be related
to sex differences. Three studies that have investigated
circulating IL-6 in relation to colorectal cancer risk observed
no association [48, 50], and two studies on TNF-alpha and
colorectal cancer risk did not observe an association [50,
51••]. In a case-cohort study within the Women’s Health
Initiative published during the past year, high levels of IL-6
were positively associated with risk of colorectal cancer, but
the effect was likely to be mediated by insulin [51••]. To
further elucidate the causal role of chronic inflammation as
assessed by CRP, with colorectal cancer, a number of studies
have investigated the association of CRP polymorphisms
with disease risk [52]. Whereas two reports did not support
such a causal hypothesis [53, 54], recent evidence suggests
that certain CRP polymorphisms are associated with colo-
rectal cancer risk [55, 56].
In conclusion, the overall evidence is supportive of
obesity-related inflammatory processes as etiological factors
for colon cancer, particularly in men, but more research is
needed to clarify the extent to which these observations may
be mediated by insulin resistance.
Alterations in Adipokine Concentrations
As stated earlier, the adipose tissue is an active endocrine
organ that secretes a number of cytokines and hormones,
which collectively are termed “adipokines” [57]. Among the
large number of newly discovered adipokines, leptin,
adiponectin, and resistin mostly have been considered
to be potential mediators of the effects of obesity on
cancer development [58].
Leptin
Leptin is a long-term regulator of food intake and energy
balance acting in the hypothalamus, but it also exerts a
number of effects purportedly relevant for carcinogenesis,
such as inducing tumor angiogenesis, promoting cell prolif-
eration and migration, interacting with metabolic and
growth factors, and increasing estrogen biosynthesis [59].
Experimental studies have shown that leptin stimulates the
proliferation and invasiveness of human colon cancer cells
and may be directly related to risk of colorectal cancer [60].
In addition, energy balance, inflammation and insulin-
signaling, which have been identified as contributors to the
development of colon cancer, also are partly regulated by
leptin. The association between leptin and colorectal cancer
risk has been investigated in several observational studies
[51••, 61–65]. Two Scandinavian studies [63, 64] reported
that leptin was associated with risk for colon cancer in men
but not in women, whereas an association in women was
reported in the Japan Collaborative Cohort Study [65] and in
the Women's Health Initiative [51••]. In the latter study,
leptin was associated with colorectal cancer risk indepen-
dent of insulin. The effects of leptin are mediated by mem-
brane protein receptors, which also circulate in soluble form
in plasma [66]. The major leptin binding protein, soluble
leptin receptor (sOB-R), may act as a negative regulator of
leptin’s physiological functions or it may serve as a slow-
release reservoir [67]. sOB-R is inversely associated with
several important colorectal cancer risk factors, such as
obesity [68], insulin resistance [69], and diabetes [70] and
thus may be related to colorectal cancer risk [71]. The first
evidence for an inverse association between sOB-R and
colorectal cancer risk was found recently in the EPIC study
[72]. In contrast, in EPIC, leptin levels were not related to
colorectal cancer risk after adjustment for BMI and waist
circumference. In this study, sOB-R concentrations were
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strongly inversely associated with colorectal cancer
risk, independent of adiposity measures, baseline leptin
concentrations, and metabolic markers. Lower leptin
binding to the leptin receptor has been shown for a
SNP (rs1137101) of the leptin receptor (LEPR) gene,
which also was related to obesity [73] and insulin
sensitivity [74]. However, the evidence of the associa-
tion between genetic variation in leptin and colorectal
cancer risk is scarce; only one study has reported a
positive association [75].
Adiponectin
In contrast to other adipokines, adiponectin is inversely
related to obesity and metabolic alterations [76]. Adiponec-
tin is involved in the regulation of energy homeostasis,
vascular reactivity, inflammation, cell proliferation, and tis-
sue remodeling [77]. It also inhibits cancer cell growth [78]
and induces apoptosis [79] and thus may be directly impli-
cated in cancer development. The evidence on the associa-
tion between adiponectin and colorectal cancer has been
summarized by two recent meta-analyses [80, 81]. In the
study by Xu et al. [81], a 2 % decreased risk of colorectal
neoplasm for a 1 μg/mL increment in adiponectin levels was
observed (odds ratio (OR), 0.98; 95 % CI, 0.96-0.99),
whereas among women there was no evidence of such a
trend (OR, 0.99; 95 % CI, 0.97-1.01). An et al. 2012 [80]
suggested that adiponectin levels seemed to be related to
colorectal cancer risk only in case–control studies or small
sample size studies (n<100) but not in nested case–control
studies or large sample size studies. Adiponectin circulates
in plasma as a trimer, a hexamer, and a high-molecular-
weight (HMW) form. HMW and non-HMW-adiponectin
fractions possess different biological activities, with HMW
form being more closely related to insulin sensitivity, where-
as complexes with lower molecular weight (i.e., non-HMW-
adiponectin) having stronger anti-inflammatory potential
[82]. Different roles of adiponectin fractions in terms of
colorectal cancer risk have been recently suggested in a
report from the EPIC study [83]. In this study, circulating
prediagnostic concentrations of total adiponectin and non-
HMW-adiponectin were inversely associated with risk of
colorectal cancer, independent of dietary and lifestyle fac-
tors. In contrast, HMW-adiponectin concentrations were not
statistically significantly related to colorectal cancer. These
data suggest that adiponectin is inversely associated with
risk of colorectal cancer and that this association is largely
accounted for by non-HMW-adiponectin. Studies that in-
vestigated the association between genetic variants at the
adiponectin locus and the risk of colorectal cancer
reported conflicting results; some studies showed signif-
icant associations [84, 85], whereas other studies did not
observe any association [86].
Resistin
Resistin is a proinflammatory mediator belonging to the
inflammatory zones (FIZZ) family also known as RELMs,
resistin-like molecules [87]. It is mainly secreted by adipose
tissue, but it has been found also in macrophages, neutro-
phils, and other cell types [88]. Resistin-like molecule beta
(RELM beta) is overexpressed in human colon cancer cells
[89]. Although resistin was proposed to be a hormone link-
ing obesity to insulin resistance in rodents, in humans the
role of resistin in metabolic deregulations was controversial
[90]. However, some genetic studies have demonstrated an
association between resistin and insulin resistance and obe-
sity [91]. The proinflammatory potential of resistin, together
with its association with obesity, suggest that it may be
another potential mediator that links colorectal cancer with
inflammation and obesity. The role of resistin in colorectal
cancer has been proposed by several epidemiological stud-
ies [62, 92, 93]. More evidence from large, prospective
studies would improve understanding these associations.
Other Factors
In addition to the metabolic pathways discussed earlier,
other potential mechanisms for the association between
body fatness and colorectal cancer risk have been proposed.
Thus, obesity-related changes in sex hormone levels were
suggested to be linked to colorectal cancer risk. For in-
stance, high body fatness is associated with higher endoge-
nous estrogen levels, and a prospective study among
postmenopausal women observed a significant association
between high endogenous estradiol levels and higher risk of
colorectal cancer [94]. The positive association was unaf-
fected by adjustment for waist circumference, insulin, and
free IGF-1, which led the authors to the conclusion that a
pathway involving endogenous estradiol may exist that is
independent of the pathway broadly associated with obesity,
hyperinsulinemia, and IGF-1. A second prospective study of
postmenopausal women observed positive associations be-
tween endogenous estrone but not estradiol and colorectal
cancer risk [95].
Alterations in the immune response, in the nuclear factor
kappa B (NF-kappa B) system, in oxidative stress, and in
peroxidation are alternative mechanisms that may link obe-
sity to colorectal cancer risk [58]. For example, increased
blood levels of oxidative stress markers have been observed
in patients with familial adenomatous polyposis [96] and
colorectal cancer [97, 98]. However, a recent nested case–
control study in EPIC suggested that the association be-
tween oxidative stress indicators, such as reactive oxygen
metabolites (ROM), and colorectal cancer risk is a result of
reactive oxygen species (ROS) production by preclinical
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tumors, rather than a causal factor in carcinogenesis (reverse
causation) [99]. Studies with longer follow-up and com-
bined measures of reactive oxygen exposure and antioxidant
status are needed to further explore the association between
oxidative stress and colorectal cancer risk.
Conclusions
The current body of evidence points to a causal role of
obesity, and in particular abdominal obesity, in the develop-
ment of colorectal cancer. Biomarker studies support the
hypothesis that this association is mediated by obesity-
related alterations, including hyperinsulinemia, chronic
low-grade inflammation, and abnormal adipokine levels,
such as adiponectin and leptin. The research pertaining to
the biological factors explaining the positive association
between body fatness and risk of colorectal cancer is not
only relevant for understanding disease etiology but also for
public health prevention activities. For risk prediction of
colorectal cancer, a more precise characterization of the
risk-defining obesity phenotype is necessary, which may
be achieved in a simple way by measuring WC in addition
to BMI but also by using biomarkers as predictive measure-
ments. It has been estimated that in Europe 10.9 % of colon
cancer cases in men and 2.6 % in women are attributable to
excess BMI (≥25 kg/m2) [100]. Considering that abdominal
obesity is more closely associated with colorectal cancer
risk than general obesity as represented by BMI, it is likely
that the proportion of colorectal cancer disease burden at-
tributable to excess body fatness is even higher.
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